EUVIMEDEUVIMED entdecken
Crossref

Adropin as a Novel Biomarker in the Diagnosis of Acute Pulmonary Embolism: a Prospective Analysis

B Gulen, H İ Celik, G Bozkus, Y Ugurlu, A Kocyigit

Clinical Laboratory · 2026

DOI: 10.7754/clin.lab.2025.251024 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Laboratory, 2026. Verfasst von B Gulen und 4 weiteren Autor:innen. Hauptthemen laut MEDLINE: Pulmonary Embolism, Intercellular Signaling Peptides and Proteins, Peptides.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pulmonary embolism (PE) is a potentially life-threatening condition requiring rapid diagnosis and management. While computed tomography pulmonary angiography (CTPA) is the gold standard for diagnosis, its overuse raises concerns about radiation exposure and healthcare costs. The objective of this study was to evaluate the diagnostic performance of serum adropin (ADR) levels in patients presenting to the emergency department with suspected acute PE. METHODS: This prospective, cross-sectional study included 120 patients who underwent CTPA due to suspected PE. Serum ADR levels were measured using ELISA. Patients were stratified by Wells score into low, moderate, and high-risk groups. Receiver operating characteristic (ROC) analysis was used to determine the diagnostic accuracy of ADR for predicting PE. RESULTS: Of the 120 patients, 40% had confirmed PE (n = 48) of patients. Median ADR levels were lower in patients with PE than in those without PTE (419, IQR: 270 - 512 vs. 481.6, IQR: 375 - 606, respectively; p = 0.03). This was also true for patients with chronic disease when compared to patients without chronic disease (413, IQR: 264 - 534 vs. 500, IQR: 433 - 685, respectively; p = 0.01). ROC analysis revealed an AUC value of 0.612 (95% CI: 0.510 - 0.714; p = 0.032) for ADR in diagnosing PE. CONCLUSIONS: While ADR alone is insufficient as a primary diagnostic tool for PE, it may serve as a complementary biomarker particularly in D-dimer positive patients with low clinical probability at specific cutoff values. However, prospective studies are warranted to validate this approach.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmbolismIntercellular Signaling Peptides and ProteinsPeptidesHumansBiomarkersFemaleProspective StudiesMaleCross-Sectional StudiesMiddle AgedROC CurveAgedBlood ProteinsAcute DiseaseComputed Tomography AngiographyPredictive Value of TestsEnzyme-Linked Immunosorbent Assay

Substanzen

BiomarkersBlood ProteinsEnho protein, humanIntercellular Signaling Peptides and ProteinsPeptides

Zitieren

APA

Gulen, B., Celik, H. İ., Bozkus, G., Ugurlu, Y., & Kocyigit, A. (2026). Adropin as a Novel Biomarker in the Diagnosis of Acute Pulmonary Embolism: a Prospective Analysis. Clinical Laboratory. https://doi.org/10.7754/clin.lab.2025.251024

Vancouver

Gulen B, Celik Hİ, Bozkus G, Ugurlu Y, Kocyigit A. Adropin as a Novel Biomarker in the Diagnosis of Acute Pulmonary Embolism: a Prospective Analysis. Clinical Laboratory. 2026. doi:10.7754/clin.lab.2025.251024

BibTeX
@article{Gulen2026,
  author = {Gulen, B and Celik, H İ and Bozkus, G and Ugurlu, Y and Kocyigit, A},
  title = {Adropin as a Novel Biomarker in the Diagnosis of Acute Pulmonary Embolism: a Prospective Analysis},
  journal = {Clinical Laboratory},
  year = {2026},
  doi = {10.7754/clin.lab.2025.251024}
}
Kostenlos starten →